KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Goodwill (2016 - 2025)

Jazz Pharmaceuticals has reported Goodwill over the past 16 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly results put Goodwill at $1.8 billion for Q4 2025, up 6.58% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 6.58% YoY), and the annual figure for FY2025 was $1.8 billion, up 6.58%.
  • Goodwill for Q4 2025 was $1.8 billion at Jazz Pharmaceuticals, roughly flat from $1.8 billion in the prior quarter.
  • Over the last five years, Goodwill for JAZZ hit a ceiling of $1.9 billion in Q2 2021 and a floor of $938.4 million in Q1 2021.
  • Median Goodwill over the past 5 years was $1.7 billion (2023), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Goodwill: soared 105.63% in 2021 and later fell 13.89% in 2022.
  • Jazz Pharmaceuticals' Goodwill stood at $1.8 billion in 2021, then dropped by 7.38% to $1.7 billion in 2022, then increased by 3.57% to $1.8 billion in 2023, then decreased by 2.1% to $1.7 billion in 2024, then grew by 6.58% to $1.8 billion in 2025.
  • The last three reported values for Goodwill were $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025) per Business Quant data.